Raymond James Financial
NAGE

Raymond James Financial’s Niagen Bioscience NAGE Stock Holding History

Raymond James Financial’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-242,411
Closed -$1.07M – 5617
2026
Q1 		$1.07M Sell
242,411
-69,691
-22% -$376K ﹤0.01% 3800
2025
Q4 		$1.98M Sell
312,102
-5,823
-2% -$40.5K ﹤0.01% 3282
2025
Q3 		$2.97M Buy
317,925
+9,711
+3% +$98.1K ﹤0.01% 2872
2025
Q2 		$4.44M Buy
308,214
+160,136
+108% +$1.58M ﹤0.01% 2454
2025
Q1 		$1.02M Sell
148,078
-6,151
-4% -$38.7K ﹤0.01% 3471
2024
Q4 		$818K Buy
+154,229
New +$844K ﹤0.01% 3582

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Raymond James Financial's NAGE Position: Q2 2026 in Review

Raymond James Financial sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 242,411 shares — an estimated $1.07M sold.

Raymond James Financial first reported a position in NAGE in Q4 2024 and held it in 6 quarters. The position peaked at $4.44M in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Raymond James Financial reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 242,411 Niagen Bioscience shares in Q2 2026, an estimated $1.07M.
  • Raymond James Financial first reported a position in Niagen Bioscience in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Niagen Bioscience position peaked at $4.44M in Q2 2025.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.